Molecular pathogenesis of IDH mutations in gliomas

Brain Tumor Pathology

Volumn 29, Issue 3, 2012, Pages 131-139

  Ichimura, Koichi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Astrocytoma; D 2 Hydroxyglutarate; G CIMP; IDH1; Oligodendroglioma

Indexed keywords

2 HYDROXYGLUTARIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; ISOCITRATE DEHYDROGENASE 3; PROTEIN P53; UNCLASSIFIED DRUG;

ASTROCYTOMA; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CONFERENCE PAPER; DEXTRO 2 HYDROXYGLUTARATE DEHYDROGENASE GENE; DNA DAMAGE; ENZYME ACTIVITY; ENZYME BINDING; GENE EXPRESSION REGULATION; GENE LOSS; GENE MUTATION; GENETIC ASSOCIATION; GLIOBLASTOMA; GLIOMA; HUMAN; ISOCITRATE DEHYDROGENASE 1 GENE; ISOCITRATE DEHYDROGENASE 2 GENE; LEVO 2 HYDROXYGLUTARATE DEHYDROGENASE GENE; MISSENSE MUTATION; MOLECULAR PATHOLOGY; MUTATOR GENE; OLIGODENDROGLIOMA; OXIDATIVE STRESS; PROTEIN FUNCTION; SURVIVAL TIME; TUMOR SUPPRESSOR GENE;

BRAIN NEOPLASMS; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MUTATION;

EID: 84865218876     PISSN: 14337398     EISSN: 1861387X     Source Type: Journal    
DOI: 10.1007/s10014-012-0090-4     Document Type: Conference Paper

References (64)

1. Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812
2. Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773
3. Reitman ZJ, Yan H (2010) Isocitrate dehydrogenase 1 and 2 mutations in cancer: Alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 102:932-941
4. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597-602
5. Jones DT, Mulholland SA, Pearson DM et al (2011) Adult grade II diffuse astrocytomas are genetically distinct from and more aggressive than their paediatric counterparts. Acta Neuropathol 121:753-761
6. Ichimura K, Pearson DM, Kocialkowski S et al (2009) IDH1 mutations are present in the majority of common adult gliomas but are rare in primary glioblastomas. Neuro Oncol 11:341-347
7. Korshunov A, Meyer J, Capper D et al (2009) Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 118: 401-405
8. Green A, Beer P (2010) Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 362:369-370
9. Kosmider O, Gelsi-Boyer V, Slama L et al (2010) Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 24:1094-1096
10. Mardis ER, Ding L, Dooling DJ et al (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361:1058-1066
11. Amary MF, Bacsi K, Maggiani F et al (2011) IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 224:334-343
12. Amary MF, Damato S, Halai D et al (2011) Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet 43:1262-1265
13. Pansuriya TC, van Eijk R, d'Adamo P et al (2011) Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet 43:1256-1261
14. Bleeker FE, Lamba S, Leenstra S et al (2009) IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 30:7-11
15. Kang MR, Kim MS, Oh JE et al (2009) Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 125:353-355
16. Shibata T, Kokubu A, Miyamoto M, Sasajima Y, Yamazaki N (2011) Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. Am J Pathol 178:1395-1402
17. Yen KE, Bittinger MA, Su SM, Fantin VR (2010) Cancer-associated IDH mutations: Biomarker and therapeutic opportunities. Oncogene 29:6409-6417
18. Hartmann C, Meyer J, Balss J et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1,010 diffuse gliomas. Acta Neuropathol 118:469-474
19. Pusch S, Sahm F, Meyer J, Mittelbronn M, Hartmann C, von Deimling A (2011) Glioma IDH1 mutation patterns off the beaten track. Neuropathol Appl Neurobiol 37:428-430
20. Hartmann C, Hentschel B, Wick W et al (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: Implications for classification of gliomas. Acta Neuropathol 120:707-718
21. Jenkins RB, Blair H, Ballman KV et al (2006) A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852-9861 (Pubitemid 44672036)
22. Ohgaki H, Kleihues P (2011) Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol 28:177- 183
23. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149-1153
24. Zhao S, Lin Y, Xu W et al (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF- 1alpha. Science 324:261-265
25. Jin G, Reitman ZJ, Spasojevic I et al (2011) 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. PLoS ONE 6:e16812
26. Dang L, White DW, Gross S et al (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 465:966
27. Xu W, Yang H, Liu Y et al (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutaratedependent dioxygenases. Cancer Cell 19:17-30
28. Williams SC, Karajannis MA, Chiriboga L, Golfinos JG, von Deimling A, Zagzag D (2011) R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1alpha upregulation in adult glioma. Acta Neuropathol 121:279-281
29. Noushmehr H, Weisenberger DJ, Diefes K et al (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510-522
30. Figueroa ME, Abdel-Wahab O, Lu C et al (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553-567
31. Turcan S, Rohle D, Goenka A et al (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature Epub ahead of print
32. Lu C, Ward PS, Kapoor GS et al (2012) IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature Epub ahead of print
33. Aghili M, Zahedi F, Rafiee E (2009) Hydroxyglutaric aciduria and malignant brain tumor: A case report and literature review. J Neurooncol 91:233-236
34. Krell D, Assoku M, Galloway M, Mulholland P, Tomlinson I, Bardella C (2011) Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma. PLoS ONE 6:e19868
35. Brehmer S, Pusch S, Schmieder K, von Deimling A, Hartmann C (2011) Mutational analysis of D2HGDH and L2HGDH in brain tumours without IDH1 or IDH2 mutations. Neuropathol Appl Neurobiol 37:330-332
36. Jin SG, Jiang Y, Qiu R et al (2011) 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res 71:7360-7365
37. Kim YH, Pierscianek D, Mittelbronn M et al (2011) TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations. J Clin Pathol 64:850-852
38. Dringen R, Bishop GM, Koeppe M, Dang TN, Robinson SR (2007) The pivotal role of astrocytes in the metabolism of iron in the brain. Neurochem Res 32:1884-1890 (Pubitemid 47497889)
39. Pratico D (2008) Oxidative stress hypothesis in Alzheimer's disease: A reappraisal. Trends Pharmacol Sci 29:609-615
40. Maynard S, Schurman SH, Harboe C, de Souza-Pinto NC, Bohr VA (2009) Base excision repair of oxidative DNA damage and association with cancer and aging. Carcinogenesis 30:2-10
41. Townsend DM, Tew KD, Tapiero H (2003) The importance of glutathione in human disease. Biomed Pharmacother 57:145-155 (Pubitemid 36740460)
42. Lee SM, Koh HJ, Park DC, Song BJ, Huh TL, Park JW (2002) Cytosolic NADP(?)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic Biol Med 32:1185-1196 (Pubitemid 34603355)
43. Mailloux RJ, Beriault R, Lemire J et al (2007) The tricarboxylic acid cycle, an ancient metabolic network with a novel twist. PLoS ONE 2:e690
44. Kim SY, Park JW (2003) Cellular defense against singlet oxygeninduced oxidative damage by cytosolic NADP?-dependent isocitrate dehydrogenase. Free Radic Res 37:309-316 (Pubitemid 36181887)
45. Lieber MR (2008) The mechanism of human nonhomologous DNA end joining. J Biol Chem 283:1-5
46. Koptyra M, Cramer K, Slupianek A, Richardson C, Skorski T (2008) BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress. Leukemia 22:1969-1972
47. Luchman HA, Stechishin OD, Dang NH et al (2012) An in vivo patient-derived model of endogenous IDH1-mutant glioma. Neuro Oncol 14:184-191
48. van den Bent MJ, Dubbink HJ, Marie Y et al (2010) IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: A report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 16:1597-1604
49. Hartmann C, Hentschel B, Tatagiba M et al (2011) Molecular markers in low-grade gliomas: Predictive or prognostic? Clin Cancer Res 17:4588-4599
50. Mukasa A, Takayanagi S, Saito K et al (2011) Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. Cancer Sci
51. Sanson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150-4154
52. Tabatabai G, Stupp R, van den Bent MJ et al (2010) Molecular diagnostics of gliomas: The clinical perspective. Acta Neuropathol 120:585-592
53. Lai A, Kharbanda S, Pope WB et al (2011) Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 29:4482-4490
54. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15:6002-6007
55. Horbinski C, Kofler J, Kelly LM, Murdoch GH, Nikiforova MN (2009) Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol 68:1319-1325
56. Capper D, Reuss D, Schittenhelm J et al (2011) Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol 121:241-252
57. Riemenschneider MJ, Jeuken JW, Wesseling P, Reifenberger G (2010) Molecular diagnostics of gliomas: State of the art. Acta Neuropathol 120:567-584
58. Andronesi OC, Kim GS, Gerstner E et al (2012) Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med 4:116ra4
59. Choi C, Ganji SK, Deberardinis RJ et al (2012) 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDHmutated patients with gliomas. Nat Med
60. Felsberg J, Wolter M, Seul H et al (2010) Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based onDNApyrosequencing.ActaNeuropathol 119:501-507
61. Takano S, Tian W, Matsuda M et al (2011) Detection of IDH1 mutation in human gliomas: Comparison of immunohistochemistry and sequencing. Brain Tumor Pathol 28:115-123
62. Kaneko MK, Tian W, Takano S et al (2011) Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation. Biochem Biophys Res Commun 406:608-613
63. Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170:1445-1453 (Pubitemid 47339290)
64. Jones DT, Kocialkowski S, Liu L et al (2008) Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68:8673-8677